发明名称 Histone demethylase inhibitors
摘要 The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
申请公布号 US8969343(B2) 申请公布日期 2015.03.03
申请号 US201314134989 申请日期 2013.12.19
申请人 Quanticel Pharmaceuticals, Inc. 发明人 Kanouni Toufike;Stafford Jeffrey Alan;Veal James Marvin;Wallace Michael Brennen
分类号 A61K31/535;C07D401/00;C07D405/00;C07D401/12;C07D401/14;C07D403/12;C07D405/14;C07D413/12;C07D471/04 主分类号 A61K31/535
代理机构 Wilson Sonsini Goodrich & Rosati 代理人 Wilson Sonsini Goodrich & Rosati
主权项 1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof,wherein, X is O or NR5; R1 is hydrogen or alkyl; each R3 is independently selected from hydroxy, halogen, cyano, NH2, NHR4, N(R4)2, NHC(O)R4, NHC(O)OR4, NHC(O)NHR4, NHC(O)N(R4)2, NHS(O)2R4, NR4C(O)R4, NR4C(O)OR4, NR4C(O)NHR4, NR4C(O)N(R4)2, NR4S(O)2R4, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl; each R4 is independently selected from alkyl, aryl, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl; R5 is alkyl, alkenyl, alkynyl, aryl, aralkyl, carbocyclyl, heterocyclyl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, or heteroarylalkyl; and n is an integer selected from 0, or 1.
地址 San Diego CA US